ReviewNanomedicine (London, England)2025
The synergistic potential of ultrasound and nanomaterials for enhanced diagnosis and therapy of head and neck cancers.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultrasound and nanomaterials are becoming flexible and revolutionary approaches to diagnosing cancer, especially head and neck cancers. This review explores the synergistic combination of nanomaterials that improve diagnostic accuracy with ultrasonography. Despite the head and neck's complex anatomy, functionalized nanoparticles as contrast agents improve ultrasound resolution and tissue differentiation. Multifunctional nanomaterials go beyond imaging to give targeted drug administration, treatment monitoring, and real-time tumor visualization. They can additionally serve both diagnostic and therapeutic functions. Due to its versatility, the ultrasound-nanomaterial platform is particularly attractive for comprehensive cancer management. Future research must focus on optimizing the design of nanoparticles by enhancing their surface modification for improved biocompatibility and controlled drug-loading capacity, which are crucial for effective targeted delivery in oncology. The development of biodegradable nanoparticles with optimized pharmacokinetics will play a pivotal role in reducing systemic toxicity. This review systematically examines the integration of nanomaterials with ultrasound imaging techniques, particularly ultrasound-guided theranostics, which have the potential to enable real-time monitoring of tumor response to therapy. These advancements in nanoparticle design and ultrasound-based diagnostics can significantly improve the accuracy of early detection, precise drug delivery, and the customization of treatment strategies for head and neck cancers, ultimately enhancing patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.